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Background:  Clinical outcomes for trans-catheter (TC-PVR) and operative (S-PVR) replacement of the pulmonary valve are excellent. 
The economic cost of each method has only been compared in small series, which have not accounted for confounding variables or 
differences in practice between centers.
methods:  A retrospective cohort study of children and adults undergoing PVR with age >8 years from 1/1/2011 to 12/31/2013 at 35 centers 
contributing data to the Pediatric Health Information Systems database was performed to measure differences in inflation-adjusted cost 
(derived by ratio of cost to charges from charge data) of S-PVR and TC-PVR. A propensity score weight-adjusted multivariable regression 
model was used to account for measured confounders. Secondary outcomes included in-hospital mortality, hospital length of stay, and 
department level charges.
results:  A total of 2,109 pulmonary valve replacement procedures were performed in 2,097 subjects over the study period (14% trans-
catheter and 86% operative). In-hospital mortality was not significantly different between S-PVR and TC-PVR (0.8% vs. 0%, p=0.24). 
Length of stay was shorter following TC-PVR (median: 1 day, IQR: 1-1) than following S-PVR (median: 4 days, IQR: 3-5.5 days, p<0.0001). 
The cost of S-PVR and TC-PVR was not significantly different (2013US$50,030 vs. 2013US$51,297; p=0.89). In a multivariate propensity-
score adjusted model, there still was no significant difference in cost between S-PVR and TC-PVR (p=0.51). History of malignancy was 
associated with increased cost of pulmonary valve replacement (p=0.004), but other patient level factors including genetic syndrome, age, 
and cardiac diagnosis did not significantly affect cost of pulmonary valve replacement. Clinical and supply charges were greater for TC- 
PVR (p<0.0001) while lab, pharmacy, and other charges (all p<0.0001) were greater for S-PVR.
Conclusion:  At this time, cost of TC-PVR and S-PVR are not significantly different. Longer length of stay and associated costs of 
hospitalization drive the cost of S-PVR while the relatively expensive clinical and supply charges drive the cost of TC-PVR.
